Skip to main content
Erschienen in: Endocrine 2/2016

26.06.2015 | Original Article

A venous thromboembolism risk assessment model for patients with Cushing’s syndrome

verfasst von: Marialuisa Zilio, Linda Mazzai, Maria Teresa Sartori, Mattia Barbot, Filippo Ceccato, Viviana Daidone, Alessandra Casonato, Graziella Saggiorato, Franco Noventa, Laura Trementino, Paolo Prandoni, Marco Boscaro, Giorgio Arnaldi, Carla Scaroni

Erschienen in: Endocrine | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Cushing’s syndrome (CS) is associated with an incidence of venous thromboembolism (VTE) about ten times higher than in the normal population. The aim of our study was to develop a model for identifying CS patients at higher risk of VTE. We considered clinical, hormonal, and coagulation data from 176 active CS patients and used a forward stepwise logistic multivariate regression analysis to select the major independent risk factors for thrombosis. The risk of VTE was calculated as a ‘CS-VTE score’ from the sum of points of present risk factors. VTE developed in 20 patients (4 pulmonary embolism). The group of CS patients with VTE were older (p < 0.001) and had more cardiovascular events (p < 0.05), infections and reduced mobility (both p < 0.001), higher midnight plasma cortisol levels (p < 0.05), and shorter APTT (p < 0.01) than those without. We identified six major independent risk factors for VTE: age ≥69 years and reduced mobility were given two points each, whereas acute severe infections, previous cardiovascular events, midnight plasma cortisol level >3.15 times the normality and shortened APTT were given one point each. A CS-VTE score <2 anticipated no risk of VTE; a CS-VTE score of two mild risk (10 %); a CS-VTE score of three moderate risk (46 %); a CS-VTE score ≥4 high risk (85 %). Considering a score ≥3 as predictive of VTE, 94 % of the patients were correctly classified. A simple score helps stratify the VTE risk in CS patients and identify those who could benefit from thromboprophylaxis.
Literatur
1.
Zurück zum Zitat P. Miljic, D. Miljic, J.W. Cain, M. Korbonits, V. Popovic, Pathogenesis of vascular complications in Cushing’s syndrome. Hormones 11, 21–30 (2012)PubMed P. Miljic, D. Miljic, J.W. Cain, M. Korbonits, V. Popovic, Pathogenesis of vascular complications in Cushing’s syndrome. Hormones 11, 21–30 (2012)PubMed
2.
Zurück zum Zitat T. Mancini, B. Kola, F. Mantero, M. Boscaro, G. Arnaldi, High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin. Endocrinol. 61, 768–777 (2004)CrossRef T. Mancini, B. Kola, F. Mantero, M. Boscaro, G. Arnaldi, High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin. Endocrinol. 61, 768–777 (2004)CrossRef
3.
Zurück zum Zitat G. Arnaldi, T. Mancini, B. Polenta, M. Boscaro, Cardiovascular risk in Cushing’s syndrome. Pituitary 7, 253–256 (2004)CrossRefPubMed G. Arnaldi, T. Mancini, B. Polenta, M. Boscaro, Cardiovascular risk in Cushing’s syndrome. Pituitary 7, 253–256 (2004)CrossRefPubMed
4.
Zurück zum Zitat O.M. Dekkers, E. Horváth-Puhó, J.O. Jørgensen, S.C. Cannegieter, V. Ehrenstein, J.P. Vandenbroucke, A.M. Pereira, H.T. Sørensen, Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J. Clin. Endocrinol. Metab. 98, 2277–2284 (2013)CrossRefPubMed O.M. Dekkers, E. Horváth-Puhó, J.O. Jørgensen, S.C. Cannegieter, V. Ehrenstein, J.P. Vandenbroucke, A.M. Pereira, H.T. Sørensen, Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J. Clin. Endocrinol. Metab. 98, 2277–2284 (2013)CrossRefPubMed
5.
Zurück zum Zitat R. Van der Pas, F.W. Leebeek, L.J. Hofland, W.W. de Herder, R.A. Feelders, Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin. Endocrinol. 78, 481–488 (2013)CrossRef R. Van der Pas, F.W. Leebeek, L.J. Hofland, W.W. de Herder, R.A. Feelders, Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin. Endocrinol. 78, 481–488 (2013)CrossRef
6.
Zurück zum Zitat B. Van Zaane, E. Nur, A. Squizzato, O.M. Dekkers, M.T. Twickler, E. Fliers, V.E. Gerdes, H.R. Buller, D.P. Brandjes, Hypercoagulable state in Cushing’s syndrome: a systematic review. J. Clin. Endocrinol. Metab. 94, 2743–2750 (2009)CrossRefPubMed B. Van Zaane, E. Nur, A. Squizzato, O.M. Dekkers, M.T. Twickler, E. Fliers, V.E. Gerdes, H.R. Buller, D.P. Brandjes, Hypercoagulable state in Cushing’s syndrome: a systematic review. J. Clin. Endocrinol. Metab. 94, 2743–2750 (2009)CrossRefPubMed
7.
Zurück zum Zitat S.A. Johannesdottir, E. Horváth-Puhó, O.M. Dekkers, S.C. Cannegieter, J.O. Jørgensen, V. Ehrenstein, J.P. Vandenbroucke, L. Pedersen, H.T. Sørensen, Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 173, 743–752 (2013)CrossRefPubMed S.A. Johannesdottir, E. Horváth-Puhó, O.M. Dekkers, S.C. Cannegieter, J.O. Jørgensen, V. Ehrenstein, J.P. Vandenbroucke, L. Pedersen, H.T. Sørensen, Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 173, 743–752 (2013)CrossRefPubMed
8.
Zurück zum Zitat D.J. Stuijver, B. van Zaane, R.A. Feelders, J. Debeij, S.C. Cannegieter, A.R. Hermus, G. van den Berg, A.M. Pereira, W.W. de Herder, M.A. Wagenmakers, M.N. Kerstens, P.M. Zelissen, E. Fliers, N. Schaper, M.L. Drent, O.M. Dekkers, V.E. Gerdes, Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J. Clin. Endocrinol. Metab. 96, 3525–3532 (2011)CrossRefPubMed D.J. Stuijver, B. van Zaane, R.A. Feelders, J. Debeij, S.C. Cannegieter, A.R. Hermus, G. van den Berg, A.M. Pereira, W.W. de Herder, M.A. Wagenmakers, M.N. Kerstens, P.M. Zelissen, E. Fliers, N. Schaper, M.L. Drent, O.M. Dekkers, V.E. Gerdes, Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J. Clin. Endocrinol. Metab. 96, 3525–3532 (2011)CrossRefPubMed
9.
Zurück zum Zitat D.J. Brotman, J.P. Girod, A. Posch, J.T. Jani, J.V. Patel, M. Gupta, G.Y. Lip, S. Reddy, T.S. Kickler, Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb. Res. 118, 247–252 (2006)CrossRefPubMed D.J. Brotman, J.P. Girod, A. Posch, J.T. Jani, J.V. Patel, M. Gupta, G.Y. Lip, S. Reddy, T.S. Kickler, Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb. Res. 118, 247–252 (2006)CrossRefPubMed
10.
Zurück zum Zitat L.M. Fatti, B. Bottasso, C. Invitti, R. Coppola, F. Cavagnini, P.M. Mannucci, Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome. J. Endocrinol. Invest. 23, 145–150 (2000)CrossRefPubMed L.M. Fatti, B. Bottasso, C. Invitti, R. Coppola, F. Cavagnini, P.M. Mannucci, Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome. J. Endocrinol. Invest. 23, 145–150 (2000)CrossRefPubMed
11.
Zurück zum Zitat M. Franchini, G. Lippi, F. Manzato, P.P. Vescovi, G. Targher, Hemostatic abnormalities in endocrine and metabolic disorders. Eur. J. Endocrinol. 162, 439–451 (2010)CrossRefPubMed M. Franchini, G. Lippi, F. Manzato, P.P. Vescovi, G. Targher, Hemostatic abnormalities in endocrine and metabolic disorders. Eur. J. Endocrinol. 162, 439–451 (2010)CrossRefPubMed
12.
Zurück zum Zitat H.E. Sjoberg, M. Blomback, P.O. Granberg, Thromboembolic complications, heparin treatment and increase in coagulation factors in Cushing’s syndrome. Acta Medica Scandinavica 199, 95–98 (1976)CrossRefPubMed H.E. Sjoberg, M. Blomback, P.O. Granberg, Thromboembolic complications, heparin treatment and increase in coagulation factors in Cushing’s syndrome. Acta Medica Scandinavica 199, 95–98 (1976)CrossRefPubMed
13.
Zurück zum Zitat G.M. Patrassi, Z.R. Dal Bo, M. Boscaro, S. Martinelli, A. Girolami, Further studies on the hypercoagulable state of patients with Cushing’s syndrome. Thromb. Haemost. 54, 518–520 (1985)PubMed G.M. Patrassi, Z.R. Dal Bo, M. Boscaro, S. Martinelli, A. Girolami, Further studies on the hypercoagulable state of patients with Cushing’s syndrome. Thromb. Haemost. 54, 518–520 (1985)PubMed
14.
Zurück zum Zitat Z.R. Dal Bo, L. Fornasiero, M. Boscaro, G. Cappellato, F. Fabris, A. Girolami, Increased factor VIII associated activities in Cushing’s syndrome: a probable hypercoagulable state. Thromb. Haemost. 47, 116–117 (1982) Z.R. Dal Bo, L. Fornasiero, M. Boscaro, G. Cappellato, F. Fabris, A. Girolami, Increased factor VIII associated activities in Cushing’s syndrome: a probable hypercoagulable state. Thromb. Haemost. 47, 116–117 (1982)
15.
Zurück zum Zitat A. Casonato, E. Pontara, M. Boscaro, N. Sonino, F. Sartorello, S. Ferasin, A. Girolami, Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coagul. Fibrinolysis 10, 145–151 (1999)CrossRefPubMed A. Casonato, E. Pontara, M. Boscaro, N. Sonino, F. Sartorello, S. Ferasin, A. Girolami, Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coagul. Fibrinolysis 10, 145–151 (1999)CrossRefPubMed
16.
Zurück zum Zitat B. Ambrosi, A. Sartorio, A. Pizzocaro, E. Passini, B. Bottasso, A. Federici, Evaluation 307 of haemostatic and fibrinolytic markers in patients with Cushing’s syndrome and in patients with adrenal incidentaloma. Exp. Clin. Endocrinol. Diabetes 108, 294–298 (2000)CrossRefPubMed B. Ambrosi, A. Sartorio, A. Pizzocaro, E. Passini, B. Bottasso, A. Federici, Evaluation 307 of haemostatic and fibrinolytic markers in patients with Cushing’s syndrome and in patients with adrenal incidentaloma. Exp. Clin. Endocrinol. Diabetes 108, 294–298 (2000)CrossRefPubMed
17.
Zurück zum Zitat G.M. Patrassi, M.T. Sartori, M.L. Viero, L. Scarano, M. Boscaro, A. Girolami, The fibrinolytic potential in patients with Cushing’s disease: a clue to their hypercoagulable state. Blood Coagul. Fibrinolysis 3, 789–793 (1992)CrossRefPubMed G.M. Patrassi, M.T. Sartori, M.L. Viero, L. Scarano, M. Boscaro, A. Girolami, The fibrinolytic potential in patients with Cushing’s disease: a clue to their hypercoagulable state. Blood Coagul. Fibrinolysis 3, 789–793 (1992)CrossRefPubMed
18.
Zurück zum Zitat C. Erem, I. Nuhoglu, M. Yilmaz, M. Kocak, A. Demirel, O. Ucuncu, H.O. Ersoz, Blood coagulation and fibrinolysis in patients with Cushing’s syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor and unchanged thrombin-activatable fibrinolysis inhibitor levels. J. Endocrinol. Invest. 32, 169–174 (2009)CrossRefPubMed C. Erem, I. Nuhoglu, M. Yilmaz, M. Kocak, A. Demirel, O. Ucuncu, H.O. Ersoz, Blood coagulation and fibrinolysis in patients with Cushing’s syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor and unchanged thrombin-activatable fibrinolysis inhibitor levels. J. Endocrinol. Invest. 32, 169–174 (2009)CrossRefPubMed
19.
Zurück zum Zitat D. Kastelan, T. Dusek, I. Kraljevic, O. Polasek, Z. Giljevic, M. Solak, S.Z. Salek, J. Jelcic, I. Aganovic, M. Korsic, Hypercoagulability in Cushing’s syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 36, 70–74 (2009)CrossRefPubMed D. Kastelan, T. Dusek, I. Kraljevic, O. Polasek, Z. Giljevic, M. Solak, S.Z. Salek, J. Jelcic, I. Aganovic, M. Korsic, Hypercoagulability in Cushing’s syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 36, 70–74 (2009)CrossRefPubMed
20.
Zurück zum Zitat S. Koutroumpi, L. Spiezia, N. Albiger, M. Barbot, M. Bon, S. Maggiolo, S. Gavasso, P. Simioni, A. Frigo, F. Mantero, C. Scaroni, Thrombin generation in Cushing’s syndrome: do the conventional clotting indices tell the whole truth? Pituitary 17, 68–75 (2014)CrossRefPubMed S. Koutroumpi, L. Spiezia, N. Albiger, M. Barbot, M. Bon, S. Maggiolo, S. Gavasso, P. Simioni, A. Frigo, F. Mantero, C. Scaroni, Thrombin generation in Cushing’s syndrome: do the conventional clotting indices tell the whole truth? Pituitary 17, 68–75 (2014)CrossRefPubMed
21.
Zurück zum Zitat B. Van Zaane, E. Nur, A. Squizzato, V.E. Gerdes, H.R. Büller, O.M. Dekkers, D.P. Brandjes, Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J. Thromb. Haemost. 8, 2483–2493 (2010)CrossRefPubMed B. Van Zaane, E. Nur, A. Squizzato, V.E. Gerdes, H.R. Büller, O.M. Dekkers, D.P. Brandjes, Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J. Thromb. Haemost. 8, 2483–2493 (2010)CrossRefPubMed
22.
Zurück zum Zitat A.M. Isidori, M. Minnetti, E. Sbardella, C. Graziadio, A. Grossman, Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur. J. Endocrinol. pii: EJE-15-0308. [Epub ahead of print] PubMed PMID: 25987566 (2015) A.M. Isidori, M. Minnetti, E. Sbardella, C. Graziadio, A. Grossman, Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur. J. Endocrinol. pii: EJE-15-0308. [Epub ahead of print] PubMed PMID: 25987566 (2015)
23.
Zurück zum Zitat S. Koutroumpi, V. Daidone, M.T. Sartori, M.G. Cattini, N.M. Albiger, G. Occhi, S. Ferasin, A. Frigo, F. Mantero, A. Casonato, C. Scaroni, Venous thromboembolism in patients with Cushing’s syndrome: need of a careful investigation of the prothrombotic risk profile. Pituitary 16, 175–181 (2013)CrossRefPubMed S. Koutroumpi, V. Daidone, M.T. Sartori, M.G. Cattini, N.M. Albiger, G. Occhi, S. Ferasin, A. Frigo, F. Mantero, A. Casonato, C. Scaroni, Venous thromboembolism in patients with Cushing’s syndrome: need of a careful investigation of the prothrombotic risk profile. Pituitary 16, 175–181 (2013)CrossRefPubMed
24.
Zurück zum Zitat M. Boscaro, N. Sonino, A. Scarda, L. Barzon, F. Fallo, M.T. Sartori, G.M. Patrassi, A. Girolami, Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J. Clin. Endocrinol. Metab. 87, 3662–3666 (2002)PubMed M. Boscaro, N. Sonino, A. Scarda, L. Barzon, F. Fallo, M.T. Sartori, G.M. Patrassi, A. Girolami, Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J. Clin. Endocrinol. Metab. 87, 3662–3666 (2002)PubMed
25.
Zurück zum Zitat G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)CrossRefPubMed G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)CrossRefPubMed
26.
Zurück zum Zitat M. Boscaro, G. Arnaldi, Approach to the patient with possible Cushing’s syndrome. J. Clin. Endocrinol. Metab. 94, 3121–3131 (2009)CrossRefPubMed M. Boscaro, G. Arnaldi, Approach to the patient with possible Cushing’s syndrome. J. Clin. Endocrinol. Metab. 94, 3121–3131 (2009)CrossRefPubMed
27.
Zurück zum Zitat S. Barbar, F. Noventa, V. Rossetto, A. Ferrari, B. Brandolin, M. Perlati, E. De Bon, D. Tormene, A. Pagnan, P. Prandoni, A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score. J. Thromb. Haemost. 8, 2450–2457 (2010)CrossRefPubMed S. Barbar, F. Noventa, V. Rossetto, A. Ferrari, B. Brandolin, M. Perlati, E. De Bon, D. Tormene, A. Pagnan, P. Prandoni, A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score. J. Thromb. Haemost. 8, 2450–2457 (2010)CrossRefPubMed
28.
Zurück zum Zitat L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)CrossRefPubMedPubMedCentral L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat M. Barbot, N. Albiger, F. Ceccato, M. Zilio, A.C. Frigo, L. Denaro, F. Mantero, C. Scaroni, Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary 17, 109–117 (2014)CrossRefPubMed M. Barbot, N. Albiger, F. Ceccato, M. Zilio, A.C. Frigo, L. Denaro, F. Mantero, C. Scaroni, Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary 17, 109–117 (2014)CrossRefPubMed
30.
Zurück zum Zitat F. Ceccato, G. Antonelli, M. Barbot, M. Zilio, L. Mazzai, R. Gatti, M. Zaninotto, F. Mantero, M. Boscaro, M. Plebani, C. Scaroni, The diagnostic performance of urinary free cortisol is better than the cortisol/cortisone ratio in detecting de novo Cushing’s syndrome: the use of a LC-MS/MS method in routine clinical practice. Eur. J. Endocrinol. 171, 1–7 (2014)CrossRefPubMed F. Ceccato, G. Antonelli, M. Barbot, M. Zilio, L. Mazzai, R. Gatti, M. Zaninotto, F. Mantero, M. Boscaro, M. Plebani, C. Scaroni, The diagnostic performance of urinary free cortisol is better than the cortisol/cortisone ratio in detecting de novo Cushing’s syndrome: the use of a LC-MS/MS method in routine clinical practice. Eur. J. Endocrinol. 171, 1–7 (2014)CrossRefPubMed
31.
Zurück zum Zitat F. Ceccato, M. Barbot, M. Zilio, S. Ferasin, G. Occhi, A. Daniele, S. Mazzocut, M. Iacobone, C. Betterle, F. Mantero, C. Scaroni, Performance of salivary cortisol in the diagnosis of Cushing’s syndrome, adrenal incidentaloma, and adrenal insufficiency. Eur. J. Endocrinol. 169, 31–36 (2013)CrossRefPubMed F. Ceccato, M. Barbot, M. Zilio, S. Ferasin, G. Occhi, A. Daniele, S. Mazzocut, M. Iacobone, C. Betterle, F. Mantero, C. Scaroni, Performance of salivary cortisol in the diagnosis of Cushing’s syndrome, adrenal incidentaloma, and adrenal insufficiency. Eur. J. Endocrinol. 169, 31–36 (2013)CrossRefPubMed
32.
Zurück zum Zitat A. Casonato, E. Pontara, F. Sartorello, M.G. Cattini, M.T. Sartori, R. Padrini, A. Girolami, Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 99, 180–184 (2002)CrossRefPubMed A. Casonato, E. Pontara, F. Sartorello, M.G. Cattini, M.T. Sartori, R. Padrini, A. Girolami, Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 99, 180–184 (2002)CrossRefPubMed
33.
Zurück zum Zitat M.T. Sartori, C. Danesin, G. Saggiorato, D. Tormene, P. Simioni, L. Spiezia, G.M. Patrassi, A. Girolami, The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin. Appl. Thromb. Hemost. 9, 299–307 (2003)CrossRefPubMed M.T. Sartori, C. Danesin, G. Saggiorato, D. Tormene, P. Simioni, L. Spiezia, G.M. Patrassi, A. Girolami, The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin. Appl. Thromb. Hemost. 9, 299–307 (2003)CrossRefPubMed
34.
Zurück zum Zitat J.C. Gill, J. Endres-Brooks, P.J. Bauer, W.J. Marks Jr, R.R. Montgomery, The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69, 1691–1695 (1987)PubMed J.C. Gill, J. Endres-Brooks, P.J. Bauer, W.J. Marks Jr, R.R. Montgomery, The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69, 1691–1695 (1987)PubMed
35.
Zurück zum Zitat A. Casonato, V. Daidone, F. Sartorello, N. Albiger, C. Romualdi, F. Mantero, A. Pagnan, C. Scaroni, Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. Br. J. Haematol. 140, 230–235 (2008)CrossRefPubMed A. Casonato, V. Daidone, F. Sartorello, N. Albiger, C. Romualdi, F. Mantero, A. Pagnan, C. Scaroni, Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. Br. J. Haematol. 140, 230–235 (2008)CrossRefPubMed
36.
Zurück zum Zitat P. Simioni, A. Scudeller, P. Radossi, S. Gavasso, B. Girolami, D. Tormene, A. Girolami, Pseudo-homozygous activated protein C resistance due to double heterozygous factor V defect (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb. Haemost. 75, 422–426 (1996)PubMed P. Simioni, A. Scudeller, P. Radossi, S. Gavasso, B. Girolami, D. Tormene, A. Girolami, Pseudo-homozygous activated protein C resistance due to double heterozygous factor V defect (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb. Haemost. 75, 422–426 (1996)PubMed
37.
Zurück zum Zitat P. Simioni, D. Tormene, D. Manfrin, S. Gavasso, S. Luni, D. Stocco, A. Girolami, Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br. J. Haematol. 103, 1045–1450 (1998)CrossRefPubMed P. Simioni, D. Tormene, D. Manfrin, S. Gavasso, S. Luni, D. Stocco, A. Girolami, Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br. J. Haematol. 103, 1045–1450 (1998)CrossRefPubMed
38.
Zurück zum Zitat J.A. Hanley, B.J. McNeil, The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29–36 (1982)CrossRefPubMed J.A. Hanley, B.J. McNeil, The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29–36 (1982)CrossRefPubMed
39.
Zurück zum Zitat S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, K. Sen, L.R. Salgado, A. Colao, B.M. Biller, Pasireotide B2305 Study Group: high variability in baseline urinary free cortisol values in patients with Cushing’s disease. Clin. Endocrinol. 80, 261–269 (2014)CrossRef S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, K. Sen, L.R. Salgado, A. Colao, B.M. Biller, Pasireotide B2305 Study Group: high variability in baseline urinary free cortisol values in patients with Cushing’s disease. Clin. Endocrinol. 80, 261–269 (2014)CrossRef
40.
Zurück zum Zitat L. Trementino, G. Appolloni, C. Concettoni, M. Cardinaletti, M. Boscaro, G. Arnaldi, Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing’s syndrome. Eur. J. Endocrinol. 166, 35–42 (2012)CrossRefPubMed L. Trementino, G. Appolloni, C. Concettoni, M. Cardinaletti, M. Boscaro, G. Arnaldi, Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing’s syndrome. Eur. J. Endocrinol. 166, 35–42 (2012)CrossRefPubMed
41.
Zurück zum Zitat H. Raff, J.L. Raff, J.W. Findling, Late-night salivary cortisol as a screening test for Cushing’s syndrome. J. Clin. Endocrinol. Metab. 83, 2681–2686 (1998)PubMed H. Raff, J.L. Raff, J.W. Findling, Late-night salivary cortisol as a screening test for Cushing’s syndrome. J. Clin. Endocrinol. Metab. 83, 2681–2686 (1998)PubMed
42.
Zurück zum Zitat P. Restituto, J.C. Galofré, M.J. Gil, C. Mugueta, S. Santos, J.I. Monreal, N. Varo, Advantage of salivary cortisol measurements in the diagnosis of glucocorticoid related disorders. Clin. Biochem. 41, 688–692 (2008)CrossRefPubMed P. Restituto, J.C. Galofré, M.J. Gil, C. Mugueta, S. Santos, J.I. Monreal, N. Varo, Advantage of salivary cortisol measurements in the diagnosis of glucocorticoid related disorders. Clin. Biochem. 41, 688–692 (2008)CrossRefPubMed
Metadaten
Titel
A venous thromboembolism risk assessment model for patients with Cushing’s syndrome
verfasst von
Marialuisa Zilio
Linda Mazzai
Maria Teresa Sartori
Mattia Barbot
Filippo Ceccato
Viviana Daidone
Alessandra Casonato
Graziella Saggiorato
Franco Noventa
Laura Trementino
Paolo Prandoni
Marco Boscaro
Giorgio Arnaldi
Carla Scaroni
Publikationsdatum
26.06.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0665-z

Weitere Artikel der Ausgabe 2/2016

Endocrine 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.